What did the FDA approve Amphastar’s Rextovy nasal spray for in 2026?

In June 2026, the FDA approved Amphastar Pharmaceuticals’ Rextovy, a 4‑milligram naloxone hydrochloride nasal spray, for over‑the‑counter sale to treat opioid overdoses. The move broadens public access to naloxone, aligns with federal recovery initiatives, and encourages competition among OTC brands to expand availability and lower costs.